Dersleri yüzünden oldukça stresli bir ruh haline sikiş hikayeleri bürünüp özel matematik dersinden önce rahatlayabilmek için amatör pornolar kendisini yatak odasına kapatan genç adam telefonundan porno resimleri açtığı porno filmini keyifle seyir ederek yatağını mobil porno okşar ruh dinlendirici olduğunu iddia ettikleri özel sex resim bir masaj salonunda çalışan genç masör hem sağlık hem de huzur sikiş için gelip masaj yaptıracak olan kadını gördüğünde porn nutku tutulur tüm gün boyu seksi lezbiyenleri sikiş dikizleyerek onları en savunmasız anlarında fotoğraflayan azılı erkek lavaboya geçerek fotoğraflara bakıp koca yarağını keyifle okşamaya başlar
Reach Us +44 1223 790975


Alzheimer's and Parkinson's Diseases Face Common Challenges in Therapeutic Development: Role of the Precompetitive Consortium, Coalition Against Major Diseases | Abstract
ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Conference Proceeding

Alzheimer's and Parkinson's Diseases Face Common Challenges in Therapeutic Development: Role of the Precompetitive Consortium, Coalition Against Major Diseases

Diane Stephenson1*, Martha Brumfield1, Klaus Romero1, Janet Woodcock2, Issam Zineh2, Eric M Reiman3, Caroline Tanner4, Richard Mohs5, Walter Koroshetz6, Timothy Nicholas7, Lisa J Bain8, Derek Hill9, Les Shaw10, Johan Luthman11, Michael Ropacki12, Richard Meibach13, Peter Loupos14, Ken Marek15, James Hendrix16, Eric Karran17, George Vradenburg18, Keiju Motohashi19, Jesse M Cedarbaum20 and Mark Forrest Gordon21

1Critical Path Institute, CAMD, Tucson, AZ, USA

2Office of Clinical Pharmacology, FDA, New Hampshire Ave, Silver Spring, USA

3Banner Alzheimer’s Institute, AZ, USA

4University of California – San Francisco, San Francisco, CA, USA

5Lilly Corporate Center, Indianapolis, IN, USA

6NINDS,Bethesda, MD, USA

7Pfizer, Groton, CT, USA

8Independent Scientific & Medical Writer, Elverson, PA, USA

9Ixico, London, UK

10Hospital of the University of Pennsylvania, Philadelphia, PA, USA

11Eisai,Woodcliff Lake, , USA

12Janssen R&D, South San Francisco, CA, USA

13Novartis,East Hanover, NJ, USA

14Sanofi, Bridgewater, NJ, USA

15Institute for Neurodegenerative Disorders, New Haven, CT, USA

16Alzheimer’s Association, Chicago, IL, USA

17Alzheimer’s Research UK, Cambridge,UK

18USAgainstAD, Washington, DC, USA

19Office of New Drug II,The University of Tokyo Hospital, Tokyo, Japan

20Neurology Clinical Development, Cambridge, MA

21Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA

Corresponding Author:
Diane Stephenson, PhD
Critical Path Institute
1730 E. River Road, Tucson, AZ 85718
Tel: 520-382-1405
Fax: 520-547-3456

Received date: February 25, 2015; Accepted date: March 14, 2015; Published date: March 31, 2015

Citation: Stephenson D, Brumfield M, Romero K, Woodcock J, Zineh I, et al. (2015) Alzheimer’s and Parkinson’s Diseases Face Common Challenges in Therapeutic Development: Role of the Precompetitive Consortium, Coalition Against Major Diseases. J Alzheimers Dis Parkinsonism 5:183. doi:10.4172/2161-0460.1000183

Copyright: © 2015 Stephenson D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Alzheimer’s disease (AD) and Parkinson’s disease (PD) pose significant challenges for successful development of new therapies, with anextremely high drug trial failure rate and yet no approved disease modifying drugs available. Given the magnitude of the challenges, it has become clear that larger collaborations and multi-partner joint efforts, pooling resources and expertise,are required for theadvancement of methods and tools that are critically needed to support drug development studies. Critical Path Institute’s Coalition against Major Diseases was formed in 2008, at a time prior to the era of public private partnerships, with the mission of streamlining and de-risking drug development for AD and PD. Since its origin, the consortium has achieved several milestones including development of consensus data standards for AD and PD, a unified clinical trial database comprised of placebo data from AD therapeutic trials and regulatory endorsement of drug development tools. In addition, the consortium is progressing strongly on other initiatives, with ongoing regulatory interactions. The coalition held its annual conference at the U.S. Food and Drug Administration, where diverse stakeholders including industry, academic experts, government agency representatives, patient advocacy organizations and regulators gathered together to share their accomplishments and focus on the needs of the future. The current landscape was emphasized with focus on the need to expand the precompetitive space and enhance data sharing globally.